A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs VX 659 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 22 Jul 2017 New trial record
- 18 Jul 2017 Status changed from planning to not yet recruiting.
- 18 Jul 2017 Accordign to a Vertex Pharmaceuticals media release, the company plans to initiate this study in early August 2017.